Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed

Takeuchi,Susumu; Seike,Masahiro; Noro,Rintaro; Soeno,Chie; Sugano,Teppei; Zou,Fenfei; Uesaka,Haruka; Nishijima,Nobuhiko; Matsumoto,Masaru; Minegishi,Yuji; Kubota,Kaoru; Gemma,Akihiko

doi:10.3892/ijo.2014.2370

Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed

Authors:
- Susumu Takeuchi
- Masahiro Seike
- Rintaro Noro
- Chie Soeno
- Teppei Sugano
- Fenfei Zou
- Haruka Uesaka
- Nobuhiko Nishijima
- Masaru Matsumoto
- Yuji Minegishi
- Kaoru Kubota
- Akihiko Gemma
View Affiliations

Affiliations: Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo 113-8603, Japan, MediBIC Group, Tokyo 102-8578, Japan
Published online on: April 7, 2014 https://doi.org/10.3892/ijo.2014.2370
Pages: 1886-1894

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pemetrexed (PEM) is currently recommended as one of the standard anticancer drugs for malignant pleural mesothelioma (MPM). However, the mechanism of the sensitivity of MPM to PEM remains unclear. We analyzed the antitumor effects of PEM in six MPM cell lines by MTS assay. To identify genes associated with drug sensitivity, we conducted gene expression profiling on the same set of cell lines using GeneChips and pathway analysis. Three cell lines were sensitive to PEM. A total fo 18 transcripts and 14 genes identified by GeneChips were significantly correlated with sensitivity to PEM. Pathway analysis revealed that osteopontin (SPP1/OPN) was an important target in PEM sensitivity. Overexpression of SPP1/OPN was observed in the sensitive cells by quantitative PCR and western blot analysis. Introduction of SPP1/OPN by lentiviral vector significantly enhanced the invasion activities of MPM cells. PEM treatment with SPP1/OPN knockdown inhibited the PEM-induced cell growth-inhibitory effect in PEM-sensitive cells. Expression of SPP1/OPN and AKT phosphorylation significantly decreased after PEM treatment of the PEM-sensitive cells. High immunohistochemical expression of SPP1/OPN was observed in two of three MPM patients who had a partial response to PEM-based chemotherapy. PEM has antitumor effects in MPM cells dependent on SPP1/OPN overexpression resulting in AKT activation. Our results suggest that SPP1 may be used as a single predictive biomarker of the effectiveness of PEM treatment in MPM.

View Figures

View References

1.	Hansen J, de Klerk NH, Musk AW and Hobbs MS: Environmental exposure to crocidolite and mesothelioma: exposure-response relationships. Am J Respir Crit Care Med. 157:69–75. 1998. View Article : Google Scholar : PubMed/NCBI
2.	Robinson BWS and Lake RA: Advances in malignant mesothelioma. N Engl J Med. 353:1591–1603. 2005. View Article : Google Scholar : PubMed/NCBI
3.	Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of PEM in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
4.	Shimokawa T, Seike M, Gemma A, et al: Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules. Br J Cancer. 106:867–875. 2012. View Article : Google Scholar : PubMed/NCBI
5.	Seike M, Yanaihara N, Bowman ED, et al: Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst. 15:1257–1269. 2007. View Article : Google Scholar : PubMed/NCBI
6.	Seike M, Goto A, Harris CC, et al: MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA. 21:12085–12090. 2009. View Article : Google Scholar : PubMed/NCBI
7.	Gemma A, Li C, Kudoh S, et al: Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database. BMC Cancer. 6:1742006. View Article : Google Scholar : PubMed/NCBI
8.	Miyanaga A, Gemma A, Kudoh S, et al: Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther. 7:1923–1930. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Kikuchi S, Honda K, Yamada T, et al: Expression and gene amplification ofactinin-4 in invasive ductal carcinoma of the pancreas. Clin Cancer Res. 14:5348–5356. 2008. View Article : Google Scholar : PubMed/NCBI
10.	McCarty KS Jr, Miller LS, Cox EB, Konrath J and McCarty KS Sr: Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 109:716–721. 1985.
11.	Shih C, Chen VJ, Gossett LS, et al: LY231514, a pyrrolo [2,3-d] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 57:1116–1123. 1997.
12.	Tajima K, Ohashi R, Sekido Y, et al: Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. Oncogene. 29:1941–1951. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Ozasa H, Oguri T, Uemura T, Miyazaki M, Maeno K, Sato S and Ueda R: Significance of thymidylate synthase for resistance to PEM in lung cancer. Cancer Sci. 101:161–166. 2010. View Article : Google Scholar : PubMed/NCBI
14.	Righi L, Papotti MG, Ceppi P, et al: Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with PEM-based chemotherapy. J Clin Oncol. 28:1534–1539. 2010. View Article : Google Scholar
15.	Assaraf YG: Molecular basis of antifolate resistance. Cancer Metastasis Rev. 26:153–181. 2011. View Article : Google Scholar
16.	Baliga SS, Merrill GF, Shinohara ML and Denhardt DT: Osteopontin expression during early cerebral ischemia-reperfusion in rats: enhanced expression in the right cortex is suppressed by acetaminophen. PLoS One. 6:e145682011. View Article : Google Scholar
17.	Rangaswami H, Bulbule A and Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 16:79–87. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Donati V, Boldrini L, Fontanini G, et al: Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res. 18:6459–6465. 2005. View Article : Google Scholar : PubMed/NCBI
19.	Tuck AB and Chambers AF: The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia. 6:419–429. 2001. View Article : Google Scholar : PubMed/NCBI
20.	Thalmann GN, Sikes RA, Devoll RE, et al: Osteopontin: possible role in prostate cancer progression. Clin Cancer Res. 5:2271–2277. 1999.PubMed/NCBI
21.	Agrawal D, Chen T, Irby R, et al: Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 94:513–521. 2002. View Article : Google Scholar : PubMed/NCBI
22.	Kim J-H, Skates SJ, Uede T, et al: Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA. 287:1671–1679. 2002. View Article : Google Scholar : PubMed/NCBI
23.	Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T and Tahara E: Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer. 79:127–132. 1998. View Article : Google Scholar : PubMed/NCBI
24.	Pass HI, Lott D, Lonardo F, et al: Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 353:1564–1573. 2005. View Article : Google Scholar : PubMed/NCBI
25.	Grigoriu BD, Scherpereel A, Devos P, et al: Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 13:2928–2935. 2007. View Article : Google Scholar
26.	Hollevoet K, Nackaerts K, Meerbeeck JP, et al: Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. J Thorac Oncol. 11:1930–1937. 2011. View Article : Google Scholar : PubMed/NCBI
27.	Yuan Y, Nymoen DA, Stavnes HT, et al: Tenascin-X is a novel diagnostic marker of malignant mesothelioma. Am J Surg Pathol. 33:1673–1682. 2009. View Article : Google Scholar : PubMed/NCBI